

SKIN CANCER CLINICAL RESEARCH

Prof. Dr. med. Reinhard Dummer

University Hospital Zurich
Department of Dermatology
Gloriastrasse 31, 8091 Zürich

reinhard.dummer@usz.ch

[Website](#)



KEYWORDS — Skin cancers, translational research, drug development, cutaneous immunology and immunotherapy

SUMMARY & MISSION STATEMENT

We have intensively studied the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with best quality of life.

OVERVIEW

Professor Dummer's principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 677 papers with a cumulative impact factor of more than 5787. He was past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research from 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas. He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, EATI, URPP and past President of the European Society for Dermatological Research (ESDR). In the last 20 years, he has developed a leading skin cancer center in Zurich. This center offers best medical care and a network of clinical trials reaching from phase I to phase III. Towards research translation, he has established numerous cooperations with basic research groups at the UZH and federal University (ETH). This has resulted in improving the understanding of cutaneous malignancies.

SELECTED CANCER RELATED PUBLICATIONS

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandalà M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT **Lancet Oncol.** 2018 Mar 21

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R,....., Elashoff DA, Elashoff RM. **N Engl J Med.** 2017 Jun 8;376(23):2211-2222.

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M,....., Suci S, Testori A. **N Engl J Med.** 2016 Nov 10;375(19):1845-1855.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS,, Hodi FS, Larkin J. **N Engl J Med.** 2017 Oct 5;377(14):1345-1356.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. **N Engl J Med.** 2017 Nov 9;377(19):1813-1823.



